At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 68 enrolled
Drug / intervention
AMD3100 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study Evaluating the Safety and Efficacy of Intravenous AMD3100 for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Patients With Advanced Hematological Malignancies
In Brief
A Phase 2 clinical trial evaluating AMD3100, Leukopheresis, and 1 other intervention for Hematologic Neoplasms. Completed, enrolled 68 participants across 1 site.
Detailed Summary
To reduce the number of donors treated with IV AMD3100 who require a second collection to obtain the minimum cells necessary for allogeneic stem cell transplant.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHematologic Neoplasms
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedJun 2009
Enrollment StartAug 2009
Primary CompletionJan 2011
Study CompletionFeb 2012
TodayJul 2026
First PostedJun 5, 2009
Enrollment StartAug 1, 2009
Primary CompletionJan 1, 2011
Study CompletionFeb 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 17.1 years ago
Interventions
AMD3100drug
Leukopheresisprocedure
Stem cell transplantprocedure